News

Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

Details

Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers. IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple advanced/ metastatic solid tumors. 

AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies

Details

AYOXXA today announced that it has signed a research agreement with one of the leading pharmaceutical companies. The agreement targets the development of low volume and high sensitivity multiplex assays for aqueous humor protein profiling for biomarker identification and validation in support of drug discovery in ophthalmology. The collaboration reflects an initial phase of a multi study plan in the field of ophthalmology and is a further step to establish AYOXXA LUNARISTM system as the standard for biomarker identification and validation in translational proteomics. 

Adrenomed closes €24 million financing led by Wellington Partners and HBM

Details

Adrenomed AG, the vascular integrity company, today announced the closing of a €24 million series D financing round. The new funds will be invested in the clinical development program of lead product candidate Adrecizumab. Adrecizunab is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma Adrenomedullin concentrations (bio-ADM). 

  1. Themis publishes compelling Phase 2 results for lead vaccine candidate against Chikungunya fever in "The Lancet"
  2. Themis announces exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies
  3. sphingotec raises €20 million from HBM and Wellington Partners
  4. Carisma Therapeutics announces $53 million Series A financing
© Wellington Partners, 2019.